These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 7004664)

  • 1. Melanoma detection by enzyme-radioimmunoassay of L-dopa, dopamine, and 3-O-methyldopamine in urine.
    Faraj BA; Lawson DH; Nixon DW; Murray DR; Camp VM; Ali FM; Black M; Stacciarini W; Tarcan Y
    Clin Chem; 1981 Jan; 27(1):108-12. PubMed ID: 7004664
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Fluorimetric assay of 3-o-methyldopamine and 4-0-methyldopamine in rat urine and o-methylation of dopamine].
    Bidard JN; Cronenberger L
    C R Acad Hebd Seances Acad Sci D; 1977 Jan; 284(5):389-92. PubMed ID: 404066
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Identification of 4-O-methyldopamine in rat tissues by reverded-phase liquid chromatography (author's transl)].
    Bidard JN; Cronenberger L
    J Chromatogr; 1979 Oct; 164(2):139-54. PubMed ID: 541405
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Reduced urinary excretion of dopamine and metabolites in chronic renal parenchymal disease.
    Pestana M; Jardim H; Serrão P; Soares-da-Silva P; Guerra L
    Kidney Blood Press Res; 1998; 21(1):59-65. PubMed ID: 9661138
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Heart failure, aging, and renal synthesis of dopamine.
    Ferreira A; Bettencourt P; Pestana M; Correia F; Serrão P; Martins L; Cerqueira-Gomes M; Soares-Da-Silva P
    Am J Kidney Dis; 2001 Sep; 38(3):502-9. PubMed ID: 11532681
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Importance of urinary 3-O methyldopamine in the metabolism of adrenergic tumors].
    Dalmaz Y; Peyrin L
    Ann Endocrinol (Paris); 1975; 36(4):189-204. PubMed ID: 1203011
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In vivo assessment of decarboxylase inhibition or potentiation: urinary dopamine and L-dopa output after L-dopa administration.
    Johnson RD; Ruthven CR; Goodwin BL; Sandler M
    J Neural Transm; 1976; 38(3-4):181-91. PubMed ID: 956809
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Optimization of the hydrolysis of conjugated L-DOPA, dopamine and dihydroxyphenylacetic acid in human urine for assay by high-performance liquid chromatography with electrochemical detection.
    Tuomainen P; Männistö PT
    Eur J Clin Chem Clin Biochem; 1997 Mar; 35(3):229-35. PubMed ID: 9127745
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The measurement of 3-o-methyldopamine in urine and plasma by a rapid and specific radioimmunoassay.
    Faraj BA; Camp VM; Pruitt AW; Isaacs JW; Ali FM
    J Nucl Med; 1977 Oct; 18(10):1027-33. PubMed ID: 903469
    [TBL] [Abstract][Full Text] [Related]  

  • 10. BIA 3-202, a novel catechol-O-methyltransferase inhibitor, enhances the availability of L-DOPA to the brain and reduces its O-methylation.
    Parada A; Loureiro AI; Vieira-Coelho MA; Hainzl D; Soares-da-Silva P
    Eur J Pharmacol; 2001 May; 420(1):27-32. PubMed ID: 11412836
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of tolcapone, a novel catechol-O-methyltransferase inhibitor, on striatal metabolism of L-dopa and dopamine in rats.
    Napolitano A; Zürcher G; Da Prada M
    Eur J Pharmacol; 1995 Feb; 273(3):215-21. PubMed ID: 7737328
    [TBL] [Abstract][Full Text] [Related]  

  • 12. 3-O-methyl-alpha-methyldopamine, a urinary metabolite of p-methoxyamphetamine in dog and monkey.
    Hubbard JW; Bailey K; Midha KK; Cooper JK
    Drug Metab Dispos; 1981; 9(3):250-4. PubMed ID: 6113935
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Specific ion-exchange chromatography and fluorimetric assay for urinary 3-O-methyldopamine.
    Dalmaz Y; Peyrin L
    J Chromatogr; 1976 Jan; 116(2):379-941. PubMed ID: 1415
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Peripheral and central inhibitors of catechol-O-methyl transferase: effects on liver and brain COMT activity and L-DOPA metabolism.
    Brannan T; Prikhojan A; Yahr MD
    J Neural Transm (Vienna); 1997; 104(1):77-87. PubMed ID: 9085195
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Assessment of renal dopaminergic system activity during cyclosporine A administration in the rat.
    Pestana M; Vieira-Coelho MA; Pinto-do-O PC; Fernandes MH; Soares-da-Silva P
    Br J Pharmacol; 1995 Aug; 115(8):1349-58. PubMed ID: 8564191
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Identification of 3-O-methyl-alpha-methyldopamine as a urinary metabolite of 3,4-methylenedioxyamphetamine in dog and monkey.
    Midha KK; Cooper JK; By A; Ethier JC
    Drug Metab Dispos; 1977; 5(2):143-8. PubMed ID: 15806
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A specific radioenzymatic assay for dihydroxyphenylalanine (DOPA). Plasma dopa may be the precursor of urine free dopamine.
    Brown MJ; Dollery CT
    Br J Clin Pharmacol; 1981 Jan; 11(1):79-83. PubMed ID: 6783056
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Assessment of renal dopaminergic system activity in the nitric oxide-deprived hypertensive rat model.
    Soares-da-Silva P; Pestana M; Vieira-Coelho MA; Fernandes MH; Albino-Teixeira A
    Br J Pharmacol; 1995 Apr; 114(7):1403-13. PubMed ID: 7541690
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ibopamine, an orally active dopamine-like drug: metabolism and pharmacokinetics in dogs.
    Pocchiari F; Pataccini R; Castelnovo P; Longo A; Paro M; Casagrande C
    Arzneimittelforschung; 1986 Feb; 36(2A):341-4. PubMed ID: 3707646
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of monoamine oxidase and catechol-O-methyltransferase inhibition on dopamine turnover: a PET study with 6-[18F]L-DOPA.
    Doudet DJ; Chan GL; Holden JE; Pate BD; Morrison KS; Calne DB; Ruth TJ
    Eur J Pharmacol; 1997 Sep; 334(1):31-8. PubMed ID: 9346324
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.